Literature DB >> 21766091

Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.

R Urgesi1, G Pelecca, R Cianci, A Masini, C Zampaletta, M E Riccioni, R Faggiani.   

Abstract

BACKGROUND: Clarithromycin resistance has decreased the eradication rates of Helicobacter pylori. AIMS: To determine whether a 10-day course of sequential therapy (ST) is more effective at eradicating H pylori infection than triple therapy (TT) in the first or second line, and to assess side effects and compliance with therapy.
METHODS: One hundred sixty treatment-naive and 40 non-treatment-naive patients who were positive for H pylori infection by ¹³C-urea breath test or endoscopy were enrolled. Eighty of 160 patients underwent TT, while 80 of 160 underwent ST with omeprazole (20 mg) plus amoxicillin (1 g) twice⁄day for five days, followed by omeprazole (20 mg) with tinidazole (500 mg) twice⁄day and clarithromycin (500 mg) twice⁄day for five consecutive days. H pylori eradication was evaluated by ¹³C-urea breath test no sooner than four weeks after the end of treatment.
RESULTS: Eradication was achieved in 59 of 80 treatment-naive patients treated with TT (74%), in 74 of 80 patients treated with ST (93%), and in 38 of 40 non-treatment-naive patients (95%). Eradication rates in treatment-naive patients with ST were statistically significantly higher than TT (92.5% versus 73.7%; P=0.0015; OR 4.39 [95% CI 1.66 to 11.58]). Mild adverse effects were reported for both regimens.
CONCLUSIONS: ST appears to be a well-tolerated, promising therapy; however, randomized controlled trials with larger and more diverse sample populations are needed before it can be recommended as a first-line treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766091      PMCID: PMC3142603          DOI: 10.1155/2011/967671

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  23 in total

1.  The declaration of Helsinki 2000: ethical principles and the dignity of difference.

Authors:  S E Salako
Journal:  Med Law       Date:  2006-06

2.  Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.

Authors:  Vincenzo De Francesco; Marcella Margiotta; Angelo Zullo; Cesare Hassan; Laura Troiani; Osvaldo Burattini; Francesca Stella; Alfredo Di Leo; Francesco Russo; Stefania Marangi; Rosa Monno; Vincenzo Stoppino; Sergio Morini; Carmine Panella; Enzo Ierardi
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

3.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

Review 4.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

5.  A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection.

Authors:  J E Domínguez-Muñoz; A Leodolter; T Sauerbruch; P Malfertheiner
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

6.  Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis.

Authors:  R J Laheij; L G Rossum; J B Jansen; H Straatman; A L Verbeek
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

7.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.

Authors:  Dino Vaira; Angelo Zullo; Nimish Vakil; Luigi Gatta; Chiara Ricci; Federico Perna; Cesare Hassan; Veronica Bernabucci; Andrea Tampieri; Sergio Morini
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

8.  A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection.

Authors:  Virender K Sharma; Colin W Howden
Journal:  J Clin Gastroenterol       Date:  2004-04       Impact factor: 3.062

9.  Seven-day therapy for Helicobacter pylori in the United States.

Authors:  N Vakil; F Lanza; H Schwartz; J Barth
Journal:  Aliment Pharmacol Ther       Date:  2004-07-01       Impact factor: 8.171

10.  Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.

Authors:  L Fischbach; E L Evans
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

View more
  5 in total

1.  Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation.

Authors:  Cesare Efrati; Giorgia Nicolini; Claudio Cannaviello; Nicole Piazza O'Sed; Stefano Valabrega
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

Review 2.  Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.

Authors:  Alexander A Nijevitch; Bulat Idrisov; Elsa N Akhmadeeva; David Y Graham
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Update on triple therapy for eradication of Helicobacter pylori: current status of the art.

Authors:  Riccardo Urgesi; Rossella Cianci; Maria Elena Riccioni
Journal:  Clin Exp Gastroenterol       Date:  2012-09-17

Review 4.  Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies.

Authors:  Ju Yup Lee; Kyung Sik Park
Journal:  Gastroenterol Res Pract       Date:  2016-12-13       Impact factor: 2.260

5.  Rescue Therapies for H. pylori Infection in Italy.

Authors:  Vincenzo De Francesco; Angelo Zullo; Luigi Gatta; Raffaele Manta; Matteo Pavoni; Ilaria Maria Saracino; Giulia Fiorini; Dino Vaira
Journal:  Antibiotics (Basel)       Date:  2021-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.